Costamare (CMRE) Shareholder Portolan Capital Management Trimmed Position; As Alnylam Pharmaceuticals (ALNY) Share Value Rose, Holder Bb Biotech Ag Lowered Its Holding by $7.62 Million

April 17, 2018 - By Nellie Frank

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

George Mccabe decreased its stake in Costamare Inc. (CMRE) by 47.23% based on its latest 2017Q4 regulatory filing with the SEC. Portolan Capital Management Llc sold 242,007 shares as the company’s stock rose 5.46% while stock markets declined. The hedge fund run by George Mccabe held 270,356 shares of the marine transportation company at the end of 2017Q4, valued at $1.56M, down from 512,363 at the end of the previous reported quarter. Portolan Capital Management Llc who had been investing in Costamare Inc. for a number of months, seems to be less bullish one the $732.15 million market cap company. The stock decreased 0.37% or $0.03 during the last trading session, reaching $6.7. About 426,650 shares traded. Costamare Inc. (NYSE:CMRE) has declined 0.48% since April 17, 2017 and is downtrending. It has underperformed by 12.03% the S&P500.

Bb Biotech Ag decreased its stake in Alnylam Pharmaceuticals Inc. (ALNY) by 5.4% based on its latest 2017Q4 regulatory filing with the SEC. Bb Biotech Ag sold 60,000 shares as the company’s stock rose 5.82% while stock markets declined. The institutional investor held 1.05 million shares of the health care company at the end of 2017Q4, valued at $133.57M, down from 1.11M at the end of the previous reported quarter. Bb Biotech Ag who had been investing in Alnylam Pharmaceuticals Inc. for a number of months, seems to be less bullish one the $9.85 billion market cap company. The stock increased 2.60% or $2.49 during the last trading session, reaching $98.33. About 721,829 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 150.73% since April 17, 2017 and is uptrending. It has outperformed by 139.18% the S&P500.

Bb Biotech Ag, which manages about $3.55 billion US Long portfolio, upped its stake in Esperion Therapeutics Inc. (NASDAQ:ESPR) by 265,000 shares to 2.36 million shares, valued at $155.58M in 2017Q4, according to the filing. It also increased its holding in Celgene Corp (NASDAQ:CELG) by 240,000 shares in the quarter, for a total of 3.42M shares, and has risen its stake in Five Prime Therapeutics Inc. (NASDAQ:FPRX).

Among 24 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 17 have Buy rating, 1 Sell and 6 Hold. Therefore 71% are positive. Alnylam Pharmaceuticals had 103 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Saturday, August 22 by TheStreet. On Thursday, September 21 the stock rating was maintained by Credit Suisse with “Outperform”. Chardan Capital Markets maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Friday, July 7 with “Buy” rating. Piper Jaffray maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Thursday, March 22. Piper Jaffray has “Buy” rating and $182.0 target. On Wednesday, March 9 the stock rating was maintained by JMP Securities with “Market Outperform”. The rating was maintained by BMO Capital Markets on Thursday, August 10 with “Buy”. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Outperform” rating given on Friday, August 28 by JMP Securities. Stifel Nicolaus maintained the stock with “Hold” rating in Thursday, October 6 report. Nomura maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Friday, February 9. Nomura has “Sell” rating and $86.0 target. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has “Outperform” rating given on Thursday, October 6 by FBR Capital.

Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on May, 4. They expect $-1.48 earnings per share, down 18.40% or $0.23 from last year’s $-1.25 per share. After $-1.48 actual earnings per share reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Investors sentiment increased to 2.03 in 2017 Q4. Its up 1.11, from 0.92 in 2017Q3. It increased, as 27 investors sold ALNY shares while 47 reduced holdings. 67 funds opened positions while 83 raised stakes. 90.18 million shares or 4.83% more from 86.02 million shares in 2017Q3 were reported. Wellington Management Group Incorporated Llp reported 0.26% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Winslow Evans Crocker holds 0.06% or 1,460 shares in its portfolio. Bailard invested in 3,500 shares. Td Asset Mngmt Incorporated holds 158,946 shares. Perceptive Advsr Lc owns 1.33M shares. Earnest Ptnrs Ltd Com accumulated 27 shares. Gru One Trading Limited Partnership holds 0.01% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 8,587 shares. Capital Fund owns 1,674 shares for 0% of their portfolio. World Asset invested 0.02% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Barclays Pcl holds 85,544 shares or 0.01% of its portfolio. Moreover, Bluecrest Capital Mngmt has 0.02% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 4,529 shares. Westpac Banking reported 5,689 shares. Glg Prtnrs Limited Partnership invested 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Guggenheim Capital Llc stated it has 52,484 shares. Amalgamated Bancorp, New York-based fund reported 17,112 shares.

Since January 4, 2018, it had 0 insider buys, and 10 selling transactions for $38.04 million activity. 27,823 shares valued at $4.17 million were sold by SCHIMMEL PAUL on Tuesday, March 13. Greene Barry E also sold $5.50M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Wednesday, March 14. Mason Michael sold $4.84 million worth of stock or 36,745 shares. KEATING LAURIE sold $234,033 worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) on Tuesday, March 20. Greenstreet Yvonne sold $985,958 worth of stock or 7,221 shares. $2.57M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was sold by Ausiello Dennis A.

Among 6 analysts covering Costamare (NYSE:CMRE), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Costamare had 13 analyst reports since December 18, 2015 according to SRatingsIntel. The company was maintained on Tuesday, October 10 by Stifel Nicolaus. The stock of Costamare Inc. (NYSE:CMRE) has “Overweight” rating given on Wednesday, October 5 by JP Morgan. Credit Suisse maintained the shares of CMRE in report on Wednesday, October 25 with “Neutral” rating. As per Monday, May 1, the company rating was upgraded by Credit Suisse. The firm earned “Neutral” rating on Friday, January 29 by Credit Suisse. The firm has “Equal Weight” rating given on Monday, January 11 by Barclays Capital. The stock has “Underperform” rating by Credit Suisse on Monday, January 30. Morgan Stanley downgraded Costamare Inc. (NYSE:CMRE) on Thursday, June 30 to “Equal-Weight” rating. Morgan Stanley upgraded the stock to “Overweight” rating in Wednesday, February 1 report. JP Morgan initiated the stock with “Underweight” rating in Friday, December 18 report.

Portolan Capital Management Llc, which manages about $535.17M and $913.15 million US Long portfolio, upped its stake in Wix .Com Ltd. (NASDAQ:WIX) by 13,665 shares to 103,701 shares, valued at $5.97 million in 2017Q4, according to the filing. It also increased its holding in Nuance Communications Inc. (NASDAQ:NUAN) by 160,239 shares in the quarter, for a total of 228,153 shares, and has risen its stake in Primo Water Corporation (NASDAQ:PRMW).

Analysts await Costamare Inc. (NYSE:CMRE) to report earnings on April, 26. They expect $0.16 earnings per share, down 30.43% or $0.07 from last year’s $0.23 per share. CMRE’s profit will be $17.48 million for 10.47 P/E if the $0.16 EPS becomes a reality. After $0.17 actual earnings per share reported by Costamare Inc. for the previous quarter, Wall Street now forecasts -5.88% negative EPS growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>